Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca
DS-8201: Regulatory submission in EU for HER2 positive breast cancer in Q1 FY 2020 (Daiichi Sankyo) - Feb 1, 2020 - Regulatory submission in Japan for HER2 positive gastric cancer in Q1 FY 2020 
European regulatory • Japanese regulatory
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005468/FY2019%20Q3%20Presentation%20Material.pdf
 
Feb 1, 2020
 
 
f6f049de-1b93-40ae-b6b3-1b2f1cfa1423.jpg